Literature DB >> 28496617

Atrial Fibrillation: The New Epidemic of the Ageing World.

Wilbert S Aronow1, Maciej Banach1.   

Abstract

The prevalence of atrial fibrillation (AF) increases with age. As the population ages, the burden of AF increases. AF is associated with an increased incidence of mortality, stroke, and coronary events compared to sinus rhythm. AF with a rapid ventricular rate may cause a tachycardia-related cardiomyopathy. Immediate direct-current (DC) cardioversion should be performed in patients with AF and acute myocardial infarction, chest pain due to myocardial ischemia, hypotension, severe heart failure, or syncope. Intravenous beta blockers, diltiazem, or verapamil may be administered to reduce immediately a very rapid ventricular rate in AF. An oral beta blocker, verapamil, or diltiazem should be used in persons with AF if a fast ventricular rate occurs at rest or during exercise despite digoxin. Amiodarone may be used in selected patients with symptomatic life-threatening AF refractory to other drugs. Digoxin should not be used to treat patients with paroxysmal AF. Nondrug therapies should be performed in patients with symptomatic AF in whom a rapid ventricular rate cannot be slowed by drugs. Paroxysmal AF associated with the tachycardia-bradycardia syndrome should be treated with a permanent pacemaker in combination with drugs. A permanent pacemaker should be implanted in patients with AF and symptoms such as dizziness or syncope associated with ventricular pauses greater than 3 seconds which are not drug-induced. Elective DC cardioversion has a higher success rate and a lower incidence of cardiac adverse effects than does medical cardioversion in converting AF to sinus rhythm. Unless transesophageal echocardiography has shown no thrombus in the left atrial appendage before cardioversion, oral warfarin should be given for 3 weeks before elective DC or drug cardioversion of AF and continued for at least 4 weeks after maintenance of sinus rhythm. Many cardiologists prefer, especially in elderly patients , ventricular rate control plus warfarin rather than maintaining sinus rhythm with antiarrhythmic drugs. Patients with chronic or paroxysmal AF at high risk for stroke should be treated with long-term warfarin to achieve an International Normalized Ratio of 2.0 to 3.0. Patients with AF at low risk for stroke or with contraindications to warfarin should be treated with aspirin 325 mg daily.

Entities:  

Keywords:  Antiarrhythmic Drugs; Aspirin; Atrial Fibrillation; Beta Blockers; Cardiovascular Disease; Cardioversion; Digoxin; Pacemakers; Radiofrequency Catheter Ablation; Stroke; Warfarin

Year:  2009        PMID: 28496617      PMCID: PMC5398780          DOI: 10.4022/jafib.154

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  188 in total

1.  Correlation of paroxysmal supraventricular tachycardia, atrial fibrillation, and sinus rhythm with incidences of new thromboembolic stroke in 1476 old-old patients.

Authors:  W S Aronow; C Ahn; A D Mercando; S Epstein; H Gutstein
Journal:  Aging (Milano)       Date:  1996-02

2.  Randomized controlled study investigating the effect of biatrial pacing in prevention of atrial fibrillation after coronary artery bypass grafting.

Authors:  T Levy; G Fotopoulos; S Walker; S Rex; M Octave; V Paul; M Amrani
Journal:  Circulation       Date:  2000-09-19       Impact factor: 29.690

3.  Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators.

Authors: 
Journal:  Ann Intern Med       Date:  1992-01-01       Impact factor: 25.391

4.  Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.

Authors:  R H Falk; A Pollak; S N Singh; T Friedrich
Journal:  J Am Coll Cardiol       Date:  1997-02       Impact factor: 24.094

5.  Preliminary report of the Stroke Prevention in Atrial Fibrillation Study.

Authors: 
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

6.  Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation.

Authors:  F D Murgatroyd; S M Gibson; X Baiyan; S O'Nunain; J D Poloniecki; D E Ward; M Malik; A J Camm
Journal:  Circulation       Date:  1999-06-01       Impact factor: 29.690

7.  Effect of quinidine or procainamide versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in elderly patients with heart disease and complex ventricular arrhythmias.

Authors:  W S Aronow; A D Mercando; S Epstein; I Kronzon
Journal:  Am J Cardiol       Date:  1990-08-15       Impact factor: 2.778

8.  Paroxysmal atrial fibrillation: high frequency of embolic brain infarction in elderly autopsy patients.

Authors:  H Yamanouchi; T Mizutani; S Matsushita; Y Esaki
Journal:  Neurology       Date:  1997-12       Impact factor: 9.910

9.  Acebutolol in supraventricular arrhythmias.

Authors:  W S Aronow; S Van Camp; M Turbow; K Whittaker; M Lurie
Journal:  Clin Pharmacol Ther       Date:  1979-02       Impact factor: 6.875

10.  Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent.

Authors:  D David; E D Segni; H O Klein; E Kaplinsky
Journal:  Am J Cardiol       Date:  1979-12       Impact factor: 2.778

View more
  12 in total

1.  Hypertension associated with atrial fibrillation.

Authors:  Wilbert S Aronow
Journal:  Ann Transl Med       Date:  2017-12

2.  Analysis of postoperative complications and risk factors in patients with permanent pacemaker implantation.

Authors:  Songbo Jing; Shan Hu; Shuai Ma
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

3.  Risk factors analysis of nosocomial pneumonia in elderly patients with acute cerebral infraction.

Authors:  Yang NanZhu; Li Xin; Yun Xianghua; Chen Jun; Li Min
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

4.  Acute Brain Ischemia, Infarction and Hemorrhage in Subjects Dying with or Without Autopsy-Proven Acute Pneumonia.

Authors:  Thomas G Beach; Lucia I Sue; Anthony J Intorcia; Michael J Glass; Jessica E Walker; Richard Arce; Courtney M Nelson; Geidy E Serrano
Journal:  medRxiv       Date:  2021-03-26

Review 5.  Atrial fibrillation in the elderly population: Challenges and management considerations.

Authors:  Mohammed Salih; Osama Abdel-Hafez; Ramzi Ibrahim; Rajiv Nair
Journal:  J Arrhythm       Date:  2021-06-24

6.  Association between social phobia and the risk of arrhythmia using the Korean National Sample Cohort: a retrospective cohort study.

Authors:  Hyunkyu Kim; Wonjeong Jeong; Seung Hoon Kim; Jun Ho Seo; Jin Sun Ryu; You-Seok Kim; Jeong-Ho Seok; Sung-In Jang; Eun-Cheol Park
Journal:  BMC Psychiatry       Date:  2022-01-14       Impact factor: 3.630

7.  Healthcare Resource Utilization for Oral Anticoagulant Reversal Therapies in Non-Valvular Atrial Fibrillation/Venous Thromboembolism Patients.

Authors:  Alex C Spyropoulos; Briain O Hartaigh; Zhun Cao; Craig Lipkin; Scott B Robinson; Harjeet Caberwal; Michaela Petrini; Cheng Wang
Journal:  Cardiol Res       Date:  2022-01-10

8.  Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy.

Authors:  Hyun-Jung Lee; Hyung-Kwan Kim; Bong-Sung Kim; Kyung-Do Han; Jun-Bean Park; Heesun Lee; Seung-Pyo Lee; Yong-Jin Kim
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

9.  Cardiac arrhythmias and In-hospital mortality amongst patients with takotsubo cardiomyopathy: A retrospective study in an Italian population.

Authors:  G Malanchini; M P Del Corral; P De Filippo; P Ferrari; A Solomon; J Krepp
Journal:  Int J Cardiol Heart Vasc       Date:  2020-08-29

10.  Genetic Interactions with Age, Sex, Body Mass Index, and Hypertension in Relation to Atrial Fibrillation: The AFGen Consortium.

Authors:  Lu-Chen Weng; Kathryn L Lunetta; Martina Müller-Nurasyid; Albert Vernon Smith; Sébastien Thériault; Peter E Weeke; John Barnard; Joshua C Bis; Leo-Pekka Lyytikäinen; Marcus E Kleber; Andreas Martinsson; Henry J Lin; Michiel Rienstra; Stella Trompet; Bouwe P Krijthe; Marcus Dörr; Derek Klarin; Daniel I Chasman; Moritz F Sinner; Melanie Waldenberger; Lenore J Launer; Tamara B Harris; Elsayed Z Soliman; Alvaro Alonso; Guillaume Paré; Pedro L Teixeira; Joshua C Denny; M Benjamin Shoemaker; David R Van Wagoner; Jonathan D Smith; Bruce M Psaty; Nona Sotoodehnia; Kent D Taylor; Mika Kähönen; Kjell Nikus; Graciela E Delgado; Olle Melander; Gunnar Engström; Jie Yao; Xiuqing Guo; Ingrid E Christophersen; Patrick T Ellinor; Bastiaan Geelhoed; Niek Verweij; Peter Macfarlane; Ian Ford; Jan Heeringa; Oscar H Franco; André G Uitterlinden; Uwe Völker; Alexander Teumer; Lynda M Rose; Stefan Kääb; Vilmundur Gudnason; Dan E Arking; David Conen; Dan M Roden; Mina K Chung; Susan R Heckbert; Emelia J Benjamin; Terho Lehtimäki; Winfried März; J Gustav Smith; Jerome I Rotter; Pim van der Harst; J Wouter Jukema; Bruno H Stricker; Stephan B Felix; Christine M Albert; Steven A Lubitz
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.